The estimated Net Worth of Bros. Advisors Lp14159, L.P... is at least 734 百万$ dollars as of 11 August 2017. Bros P owns over 176,056 units of BeiGene Ltd stock worth over 734,011,454$ and over the last 7 years Bros sold BGNE stock worth over 0$.
Bros has made over 1 trades of the BeiGene Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently Bros bought 176,056 units of BGNE stock worth 12,499,976$ on 11 August 2017.
The largest trade Bros's ever made was buying 176,056 units of BeiGene Ltd stock on 11 August 2017 worth over 12,499,976$. On average, Bros trades about 88,028 units every 0 days since 2017. As of 11 August 2017 Bros still owns at least 3,476,256 units of BeiGene Ltd stock.
You can see the complete history of Bros P stock trades at the bottom of the page.
Over the last 9 years, insiders at BeiGene Ltd have traded over 1,899,158,980$ worth of BeiGene Ltd stock and bought 23,241,738 units worth 1,040,248,444$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Investment Management, Ltd....、Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of 33,382,815$. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth 1,053,695$.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: